Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05683028
Other study ID # EC/2017/0970
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 1, 2020
Est. completion date June 14, 2023

Study information

Verified date January 2024
Source University Hospital, Ghent
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Major depressive disorder (MDD) is worldwide one of the most prevalent and disabling mental health conditions. Electroconvulsive therapy (ECT) is a safe and effective treatment even though 6-month relapse rates are high. Cognitive side effects of ECT, such as reduced cognitive control, might trigger mechanisms that increase relapse in patients. As such, cognitive control training (CCT) holds promise as a non-pharmacological strategy to improve long-term effects of ECT (i.e., increase remission, and reduce depression relapse).


Description:

Eighty-eight participants aged between 18-70 years with major depressive disorder who start electroconvulsive treatment (ECT) will be included in this randomized controlled trial (RCT). Following (partial) response to ECT treatment (at least a 25% reduction of clinical symptoms), participants will be randomly assigned to a computer based CCT or active placebo control. A first aim of this RCT is to assess the effects of CCT compared to an active placebo condition on depression symptomatology, cognitive complaints, and quality of life. Secondly, participants will be monitored every two weeks for a period of six months following CCT/active placebo, allowing the detection of potential relapse of depression. Thirdly, the investigators will assess participant evaluation of the addition of cognitive remediation to ECT using qualitative interview methods (satisfaction, acceptability and appropriateness). Finally, in order to further advance our understanding of the mechanisms underlying effects of CCT, exploratory analyses may be conducted using facial video footage collected during the CCT/active control phase of the study.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date June 14, 2023
Est. primary completion date June 14, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - aged between 18 and 70 years old - current major depressive episode with treatment resistance - eligibility and consent for ECT treatment - ability to provide consent to study Exclusion Criteria: - neurodegenerative disorder or MOCA < 18 - catatonia - schizophrenia - alcohol use disorder in previous year - prior ECT treatment - insufficient computer knowledge or analphabetism

Study Design


Intervention

Behavioral:
Cognitive Control Training
Cognitive Control Training (CCT) makes use of a very basic cognitive task that strongly loads on working memory and cognitive control processes, namely the adaptive Paced Auditory Serial Addition Task (aPASAT) where participants are given a number every 3 seconds and are asked to add the number they just heard with the number they heard before. Task difficulty is modified based on the participants current task performance, allowing training of cognitive control. Participants in the intervention group will start the CCT training after completion of ECT with a maximum time interval of 7 days. Training sessions will be performed on a tablet or computer and participants will complete five sessions per week (20 minutes per session) for a period of two weeks.
Active Control
Participants in the active control group will start placebo training after completion of ECT with a maximum time interval of 7 days. The placebo task consists of a task similar to the experimental condition but that does not train cognitive control. Prior research confirmed that this condition controls for non-specific effects of the training and motivational issues. Participants will perform the sessions on a tablet or computer and complete five sessions per week (20 minutes per session) for a period of two weeks.

Locations

Country Name City State
Belgium Ghent University Hospital Ghent

Sponsors (3)

Lead Sponsor Collaborator
University Hospital, Ghent King Baudouin Foundation, University Ghent

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in severity of depressive symptoms, clinician-rated (HAM-D) The Hamilton Depression Rating Scale (HAM-D) is a clinician rated questionnaire with 17 items scored on a three or five-point Likert-type scale. Amongst other symptoms of depression, items include mood, insomnia and suicidal ideations. Higher scores indicate increased severity of depression with a maximum score of 50 and minimum of 0. 1-7 days before first ECT session, 1-7 days post ECT completion, 1-7 days after intervention/placebo completion, 3 months after ECT completion, and 6 months after ECT completion
Primary Change in severity of depressive symptoms, self-reported (BDI-II) The Beck Depression Inventory (BDI-II) is a 21-item self-report questionnaire regarding symptoms of depression with good validity and reliability. Higher scores indicate increased severity of depression. Minimum score is 0 and 63 is the maximum score. 1-7 days before first ECT session, 1-7 days post ECT completion, 1-7 days after intervention/placebo completion, 3 months after ECT completion, and 6 months after ECT completion
Primary Change in depressive symptoms and quality of life, self-reported (RDQ) The Remission from Depression Questionnaire (RDQ) will inform about seven domains: symptoms of depression, non-depressive symptoms, features of positive mental health, coping ability, functioning, life satisfaction and a general sense of well-being. The RDQ is a 41-item questionnaire. Higher scores indicate increased severity of depression. Minimum score is 0 and 82 is the maximum score. 1-7 days before first ECT session, 1-7 days post ECT completion, 1-7 days after intervention/placebo completion, 3 months after ECT completion, and 6 months after ECT completion
Secondary Subjective memory complaints (SSMQ) To assess subjective cognitive functioning the Dutch version of the Squire Subjective Memory Questionnaire (SSMQ) (Squire, Wetzel et al. 1979) will be administered. this is a self-report questionnaire consisting of 18 items. The patients' answers are scored between -4 (worse than before), 0 (same as before), and +4 (better than before) points, the sum of which are added together to obtain a final score. A negative score shows an increase in the degree of forgetfulness. 1-7 days before first ECT session, 1-7 days post ECT completion, 1-7 days after intervention/placebo completion, 3 months after ECT completion, and 6 months after ECT completion
Secondary Quality of Life in Depression Scale (QLDS) This 34-item questionnaire, developed by qualitative interviews, asks patients to rate statements regarding fulfillment of universal human needs such as 'I take good care of myself' and 'I like to know what is going on in the world'. 1-7 days before first ECT session, 1-7 days post ECT completion, 1-7 days after intervention/placebo completion, 3 months after ECT completion, and 6 months after ECT completion
Secondary Rumination (RRS-10) The Ruminative Response Scale (RRS-10) will be used to monitor rumination or repetitive negative thinking as this is a well-established cognitive risk factor for MDE. This patient-rated scale consists of 10 items. A higher score indicates a higher degree of rumination with a minimum score of 10 and maximum score of 40. 1-7 days before first ECT session, 1-7 days post ECT completion, 1-7 days after intervention/placebo completion, 3 months after ECT completion, and 6 months after ECT completion
Secondary Cognition (CANTAB) Pattern Recognition Memory (measuring visual pattern recognition memory) and One Touch Stockings of Cambridge (measuring spatial spanning and working memory). A third test, Motor Screening was included to measure general sensorimotor skills. 1-7 days before first ECT session, 1-7 days post ECT completion, 1-7 days after intervention/placebo completion, 3 months after ECT completion, and 6 months after ECT completion
Secondary Cognition (Paced Auditory Serial Addition Task - PASAT) Neuropsychological test to assess capacity and rate of information processing as well as sustained and divided attention. 1-7 days before first ECT session, 1-7 days post ECT completion, 1-7 days after intervention/placebo completion, 3 months after ECT completion and 6 months after ECT completion
Secondary Acceptability and satisfaction Qualitative interviews will be conducted with a maximum of 20 patients and family members to explore acceptability of the ECT procedure and the intervention. 1 - 30 days after CCT training completion
Secondary Time to relapse By decreasing depression symptomatology we expect a decrease in relapse rates and a prolonged time-to-relapse-interval as measured by telephone interviews, once every two weeks, in patients who achieve remission. Up to 6 months monitoring
Secondary Facial features from video footage During CCT or placebo training facial video footage will be collected from which different facial features will be extracted with the use of automated algorithms. These facial features could give insight into working processes during cognitive training versus placebo training. Certain facial features have shown to be indicative of learning, engagement and depressive symptomatology. 2 weeks during CCT or placebo intervention
See also
  Status Clinical Trial Phase
Completed NCT04469322 - Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression N/A
Recruiting NCT02481245 - BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study Phase 2
Completed NCT03449979 - Single Session of tACS in a Depressive Episode N/A
Recruiting NCT05708222 - Sleep Signal Analysis for Current Major Depressive Episode (SAMDE)
Completed NCT01879111 - Increasing the Efficiency of Depression-screening Using Patient-targeted Feedback N/A
Unknown status NCT01212848 - Transcranial Magnetic Stimulation (TMS) for Suicidal Ideation Phase 3
Not yet recruiting NCT05547711 - Prediction and Validation of Unipolar Depression With Psychosocial-somatic Markers in a Naturalistic Cohort Recruited in an Outpatient Setting N/A
Completed NCT04239521 - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Completed NCT03288714 - Adaptive Design Study of NEST sTMS in Subjects With Major Depressive Disorder N/A
Completed NCT03899168 - Confirmation Bias Towards Treatments of Depressive Disorders in Social Tagging N/A
Terminated NCT03537547 - Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder Phase 4
Recruiting NCT05910775 - Role Of Non-Specific Effects in The Treatment of Depression With Esketamine N/A
Terminated NCT04383509 - Electroconvulsive Treatment Followed by Cognitive Control Training N/A
Enrolling by invitation NCT05701345 - Study of Virtual Reality-based Medical Device for Patients With Depressive Disorder N/A
Recruiting NCT04123301 - Theta-Burst Stimulation in Major Depressive Episodes With Mixed Characteristics. N/A
Completed NCT05686408 - Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD) Phase 2
Completed NCT03543410 - A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression Phase 2
Completed NCT04953338 - Mental Health Associations With Vitiligo
Recruiting NCT06152705 - Comparing the Efficacy of fMRI-Guided vs. Standard iTBS in Treating Depression N/A
Completed NCT05462652 - Self-guided Treatment for Adolescents Navigating Depression N/A